Third-Dose BNT162b2 Vaccination Elicits Markedly High-Level SARS-CoV-2-Neutralizing Antibodies in Vaccinees Who Responded Poorly to a Second Dose in Japan
- PMID: 35580786
- PMCID: PMC9129163
- DOI: 10.1093/infdis/jiac209
Third-Dose BNT162b2 Vaccination Elicits Markedly High-Level SARS-CoV-2-Neutralizing Antibodies in Vaccinees Who Responded Poorly to a Second Dose in Japan
Conflict of interest statement
Potential conflicts of interest . All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Comment on
-
Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine.J Infect Dis. 2022 Jan 5;225(1):30-33. doi: 10.1093/infdis/jiab556. J Infect Dis. 2022. PMID: 34726239 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
